Immunotherapy Equipment
-
based in USA
SL-701 is an immunotherapy designed to direct the immune system to attack targets present on certain malignancies including brain cancer. SL-701 comprises 3 short synthetic peptides that correspond to epitopes of targets including IL-13Rα2, EphA2, and survivin; 2 of these synthetic peptides (IL-13Rα2 and survivin) are ...
-
Manufactured by BriaCell Therapeutics Corp.based in CANADA
Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that directly stimulates the body’s own cancer fighting cells to attack and destroy breast cancer tumors. ...
-
Manufactured by AIVITA Biomedical, Inc.based in USA
AIVITA’s immunotherapy technology creates personalized vaccines for cancer patients that target and eliminate tumor-initiating cells which are the seed of the disease. Used alone or in parallel with other treatments, AIVITA’s cancer immunotherapy represents a powerful new approach in the search for curative treatments for ...
-
Manufactured by AJ Vaccines A/Sbased in DENMARK
VesiCulture (BCG Culture) For the treatment of Bladder ...
-
Manufactured by MedGenome Inc.based in USA
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the ...
-
Manufactured by Gritstone Biobased in USA
of a Phase I/2 clinical study in combination with checkpoint inhibitors for the treatment of non-small cell lung cancer in patients with relevant KRAS mutations who have progressed on prior immunotherapy, and for cancer types where a relevant TP53 mutation ...
-
Manufactured by Immunethep, SAbased in PORTUGAL
Immunethep has developed an anti-bacterial immunotherapy based on the discovery of a virulence mechanism shared by a set of different pathogenic ...
-
Manufactured by Allovate Therapeuticsbased in USA
Oral mucosal immunotherapy (OMIT) is a novel form of allergen-specific immunotherapy. Immunotherapy has a 100-year track record of success for respiratory allergies. OMIT improves upon this approach by delivering immunotherapeutic agents to the areas of the oral cavity with the highest likelihood of prompting a decrease in allergy ...
-
Manufactured by OncoQR ML GmbHbased in AUSTRIA
Cancer cells have the ability to escape our immune system´s defenses – by outsmarting checkpoint molecules on our immune cells. For more than three decades, science and industry have been working to overcome cancer’s tricky battle ...
-
Manufactured by HAL Allergy Groupbased in NETHERLANDS
Subcutaneous immunotherapy (SCIT) available for major respiratory and venom allergens. Our subcutaneous (SCIT) allergoid product is designed for a faster, simpler and more effective immunotherapy to improve the patient’s convenience for the treatment of a wide range of allergic symptoms, from allergic conjunctivitis and allergic ...
-
Manufactured by Aurora Biopharmabased in USA
The human body has a powerful immune system, and one of its white blood cells called a T-cell is like a solider capable of attacking and killing abnormal cancerous cells. However, in cancer patients, these T cells are compromised, either fail to target or recognize cancerous cells, or are too few in number to lead an strong attack. Aurora’s revolutionary CAR T Cell Therapy change a cancer ...
-
Manufactured by Gritstone Biobased in USA
Our first oncology product candidate, GRANITE, is a personalized neoantigen-based immunotherapy. It is being evaluated in the Phase 2 portion of a Phase 1/2 clinical study in combination with checkpoint inhibitors for patients with microsatellite stable colorectal cancer (MSS CRC) who have progressed on FOLFOX/FOLFIRI therapy and a second ...
-
Manufactured by Hemogenyx Pharmaceuticals plcbased in UNITED KINGDOM
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal antibody against a target on the surface of AML ...
-
Manufactured by Diamyd Medical ABbased in SWEDEN
Diamyd® is a suspension for injection containing the active pharmaceutical ingredient GAD65 mixed with the vaccine adjuvant Alhydrogel (alum). The human recombinant protein GAD65 is manufactured in insect cells in a well-controlled GMP process. The manufacturing process is developed for late phase clinical use. A new manufacturing facility is being set up by Diamyd Medical in Umeå, ...
-
Manufactured by multimmune GmbHbased in GERMANY
ENKASTIM-ev is an innovative product candidate representing a new class of therapy known as Active Cellular Immunotherapies (ACIs). ACI is a treatment approach which capitalizes on the power of vital human cells to re-engage the patient's own immune system to fight cancer. The product induces a targeted immune response against surface-bound ...
-
Manufactured by Anaveon AGbased in SWITZERLAND
The culmination of our research is ANV419, which is in clinical development. It is a rationally engineered fusion protein that is a stable, antibody-like molecule. ...
-
Manufactured by OncoQR ML GmbHbased in AUSTRIA
Lead candidate TYG100 (formerly OQR100, out-licensed to TYG oncology Ltd.) is an “Active Checkpoint Control Immunotherapy (ACCI)” for the treatment of gastroenterological cancers such as pancreatic, stomach, colon, and gastro-esophageal cancer. The immunogen of TYG100 contains a small part of G17 (little ...
-
based in UNITED KINGDOM
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been engineered to be replication deficient and can be manufactured in well-established HEK293 cell lines containing the adenoviral E1 ...
-
based in USA
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue that Metaclipse modifies with a ‘protein ...
-
based in USA
Influenza (Target age 65+) and Influenza+ SARS-C0V-2 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you